Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study Academic Article 2016 uri icon

authors

  • Troya J
  • Castaño M
  • Carrero A
  • Galindo MJ
  • Suárez-Lozano I
  • Knobel H
  • Raffo M
  • Solís J
  • Yllescas M
  • Esteban H
  • González-García J
  • Ryan P
  • Berenguer J
  • Imaz A
  • GESIDA-8314 Study Group
  • Ribera E
  • Podzamczer D
  • Hontañón V
  • Terrón JA
  • BOIX MARTINEZ, VICENTE
  • Moreno S
  • Barrufet P

publication date

  • 2016